Brind.

Wells Fargo lowered its price target on September 5, 2025, following trial results related to Wave Life Sciences.

1 report, 1 independent Updated Sep 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Wells Fargo Wave Life Sciences

Keep exploring

The entities involved

Wells Fargo
American multinational banking and financial services company
- Wells Fargo volunteers in the city of Napa.18:43
- TD Cowen analysts are scrutinizing the business strategies of major financial institutions, including U.S. Bancorp and Wells Fargo, while Morgan Stanley also contributes to the inquiry.Sat 19:44
Wave Life Sciences
biotechnology company

Nothing else this week.

Related events

Wells Fargo initiated coverage of Cleveland-Cliffs on August 27, 2025, citing cost-cutting and steel price leverage.Jun 7

Coverage

Newest first; wire copies grouped

Sep 5TipRanksB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’ B. Riley reiterates a Buy rating on Wave Life Sciences (WVE) with a $19 price target after the company announced RestorAATion-2 data.